Major health systems refuse to administer Aduhelm as top FDA leaders meet behind closed doors to talk with payers
Normally when a new drug wins FDA approval, the commercial launch plays out quietly in the background for a few years, with hardly ever any FDA involvement, before there’s some consensus on whether the drug is a commercial or clinical success, failure or somewhere in between.
For Biogen’s new Alzheimer’s drug, however, that launch is kicking off with a deafening bang as two major health systems — the Cleveland Clinic and Mount Sinai — are now refusing to administer the drug. And the FDA is not only leading but funding the discussion over how insurers will deal with Aduhelm — a rarity for an agency that typically steers clear of such contention.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.